News & Media

News & Media

Press releases

May 7, 2019
Kyn Therapeutics Strengthens Leadership Team with Key Appointments

February 4, 2019
Kyn Therapeutics Appoints Douglas Carlson as Chief Financial Officer

January 18, 2019
Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies

December 19, 2018
Kyn Therapeutics Announces Initiation of Phase 1b/2 Clinical Studies of ARY-007 in Collaboration with Merck

March 21, 2018
Kyn Therapeutics Appoints Chairman and Scientific Advisory Board Member

December 14, 2017
Kyn Therapeutics Announces $49 Million Series A Capital Available to Develop Cancer Therapy Candidates with Novel Approaches to Major Immunometabolism Pathways

In the news

Despite Buyout, Celgene Dealmaking Rolls On With Kyn, Obsidian Tie-Ups

Endpoints News
Celgene inks first deals since Bristol-Myers announced $74B buyout — bets $80M on immunometabolism

Boston Business Journal
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup

Bloomberg Baystate Business: Biogen, Budget and ESG

view all Tweets


November is #lungcancerawareness month. Did you know that approximately 433 Americans die every day from lung cance… http://Y2Z2l4kGsH

Director of Discovery Biology Ben Amidon will be attending the 34th annual Society for Immunotherapy of Cancer (SIT… http://nJhU1zVaLy

The Society for Immunotherapy of Cancer is a not-for-profit medical professional society aiming to make the word “c… http://Py7nwxgkTE

#DYK Kyn team members have contributed to key publications in the area of immunometabolism? If learning more about… http://Z8X9qID2L8

Corporate fact sheet

download now

Media contact

David Rosen
Argot Partners


Sign up to get up-to-date news about Kyn Therapeutics.

Contact us

Find us

Kyn Therapeutics
50 Northern Avenue
7th Floor
Boston, MA 02210

Call us


Email us

Friend us